Search results
Moderna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
Barrons.com· 6 days agoFEATURE U.S. vaccine makers say that the Food and Drug Administration’s delay in designing this...
As states loosen childhood vaccine requirements, public health experts' worries grow
Medical Xpress· 7 hours agoLouisiana Republican state Rep. Kathy Edmonston believes no one ought to be required to vaccinate...
Pfizer plans to cut costs by $1.5 billion as demand for COVID vaccine dwindles
Quartz· 4 days agoPharma giant Pfizer announced Wednesday another cost-cutting initiative as the company struggles...
Better Buy: Inovio Pharmaceuticals vs. Novavax
Motley Fool via Yahoo Finance· 4 days agoThe COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs ...
Trump, used to friendly crowds, confronts repeated boos during raucous Libertarian convention speech
KIRO 7 Seattle-Tacoma· 21 hours agoLibertarians, who prioritize small government and individual freedoms, are often skeptical of the...
How a simulation is informing COVID-19 vaccine policy after our 'return to normal'
Medical Xpress· 6 days agoBefore the emergence of the omicron COVID-19 variant, countries like the U.K. had high vaccination...
Century-old vaccine found to protect type 1 diabetics from infectious diseases
Medical Xpress· 4 days agoTwo back-to-back randomized double-blinded placebo-controlled trials found that the BCG vaccine provided continuous protection for nearly the entire COVID
Novavax awaits FDA decision on whether its next COVID shot can be offered in US
Reuters· 2 days ago, opens new tab will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started ...
Why Vaccine Stocks Rallied This Week | The Motley Fool
The Motley Fool· 2 days agoShares of vaccine stocks Moderna (MRNA 1.58%), Novavax (NVAX 2.31%), and BioNTech SE (BNTX -2.07%)...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and...
The Yuma Sun· 6 days agoThe efficacy of ARCT-154 against severe COVID-19 was 100 percent in healthy persons aged 18-59 and more than 90 percent in persons at risk of severe consequences ...